$APLM News

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics FY EPS $(7.57) Up From $(52.80) YoY, Sales $8.500M

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30

Apollomics Reports First Half 2025 Financial Results

Apollomics H1 EPS $(11.37) Up From $(37.53) YoY, Sales $8.500K

Apollomics H1 EPS $(11.37) Up From $(37.53) YoY, Sales $8.500K

On December 11, 2025 Apollomics Issued Formal Notice Of Termination To Edison Oncology Related To Development And Commercialization Of APL-122; Terminating Agreement On Basis That Edison Failed To Fulfill Certain Material Performance & Reporting Obligations; Co Does Not Expect Termination To Have Material Adverse Effect On Its Overall Financial Condition Or Results Of Operations

APLM stock has given up its prior gain. Apollomics shares were trading higher after the company announced it entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment.

CORRECTION: Apollomics entered into a settlement agreement on Nov. 19

Apollomics shares are trading higher after the company announced it entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment.

Apollomics Announces Settlement of Cayman Litigation

Apollomics Enters Into Settlement Agreement With TWVC Goldlink Partners Investment And TWVC Panglin Group Investment; To Pay $5M In Cash And $879,757.78 In Associated Legal expenses

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Reported Earlier, Apollomics Appoints Ya Chi Claudia Huang To Board And Committees Following Resignation Of Po Jen Hsueh

Apollomics Receives $3.9M Payment From LaunXP, Maintains Active Collaboration On Vebreltinib Development

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Nasdaq Cancels Delisting Hearing For Apollomics, Confirms Compliance With Continued Listing Standards

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times